Eli Lilly & Co presents a complex financial and strategic profile at a critical inflection point, characterized by aggressive capital deployment toward manufacturing expansion and geographic diversification, a premium valuation
Eli Lilly & Co's value proposition has fundamentally evolved from a diversified pharmaceutical manufacturer to a dominant force in metabolic disease therapeutics, particularly obesity and diabetes treatment. The
